Travere Therapeutics Inc (NAS:TVTX)
$ 6.28 -0.28 (-4.27%) Market Cap: 478.09 Mil Enterprise Value: 463.90 Mil PE Ratio: 0 PB Ratio: 6.47 GF Score: 58/100

Q4 2023 Travere Therapeutics Inc Earnings Call Transcript

Feb 15, 2024 / 09:30PM GMT
Release Date Price: $8.74 (+5.94%)
Operator

Good day and welcome to the Travere Therapeutics' fourth quarter and full year 2023 financial results and corporate update conference call. Today's conference is being recorded. At this time, I would like to turn the conference call over to Anne Crotteau. Please go ahead, ma'am.

Anne Crotteau
Travere Therapeutics Inc - Manager, Investor Relations

Thanks, Jenny. Good afternoon and welcome to Travere Therapeutics' fourth quarter and full year 2023 financial results and corporate update call. Thank you all for joining. Today's call will be led by our President and Chief Executive Officer, Dr. Eric Dube. Eric will be joined in the prepared remarks by Dr. Jula Inrig, our Chief Medical Officer; Peter Heerma, our Chief Commercial Officer; and Chris Cline, our Chief Financial Officer. Dr. Bill Rote, Senior Vice President of Research and Development, will join up for the Q&A session.

Before we begin, I'd like to remind everyone that statements made during this call regarding matters that are not historical facts are forward-looking statements within the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot